MedPath

Alteplase

Generic Name
Alteplase
Brand Names
Activase, Cathflo, Cathflo Activase
Drug Type
Biotech
CAS Number
105857-23-6
Unique Ingredient Identifier
1RXS4UE564
Background

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischemic stroke (AIS) has increased over the years. New thrombolytic agents derived from tissue plasminogen activator, such as desmoteplase, tenecteplase and reteplase, have also been developed. Alteplase is also available as Cathflo Activase (intracatheter instillation) for the restoration of function to central venous access devices.

Indication

Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and acute pulmonary emboli accompanied by unstable hemodynamics.

Associated Conditions
Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
Clinical Trials
Related News

Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval

• The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries. • Recent FDA approvals for AI-based diagnostic tools, including JLK-LVO and Heuron ICH, mark significant advancements in early detection and treatment of brain hemorrhages. • Several pharmaceutical companies including Baxter, Pfizer, and Novartis are developing promising pipeline therapies such as tissue plasminogen activator, alteplase, and BAF312 to address the significant unmet needs in brain hemorrhage treatment.

FDA Approves Genentech's TNKase for Acute Ischemic Stroke with Simplified Administration

• The FDA has approved Genentech's TNKase, a clot-dissolving agent, for treating acute ischemic stroke in adults, marking the company's second stroke treatment approval. • TNKase offers a streamlined five-second intravenous bolus administration, presenting a significant advantage over the current standard treatment Activase's 60-minute infusion protocol. • The approval is supported by a multi-center non-inferiority study across 22 Canadian stroke centers, demonstrating comparable safety and efficacy to Activase in patients with disabling neurological deficits.

DM199's Novel Mechanism for Acute Stroke Treatment Detailed in Stroke Journal Publication

• DiaMedica's DM199, a recombinant human tissue kallikrein-1, demonstrates promising potential in acute ischemic stroke treatment by enhancing collateral circulation and stimulating angiogenesis. • The drug's mechanism involves a 36-fold increase in bradykinin B2 receptor expression in ischemic brain regions, leading to improved brain perfusion through three synergistic pathways. • Phase 2/3 ReMEDy2 trial is currently evaluating DM199's efficacy in treating acute ischemic stroke patients, with plans to enroll up to 728 patients across 100 global sites.

Remedy Pharmaceuticals to Present CIRARA Data from Phase 3 CHARM Study at ISC 2025

• Remedy Pharmaceuticals will present efficacy data from the Phase 2 GAMES-RP and Phase 3 CHARM studies of CIRARA at the International Stroke Conference (ISC) 2025. • A meta-analysis will evaluate CIRARA's efficacy in treating Large Hemispheric Infarctions (LHI) with core lesion volumes ≤ 125 mL by combining data from GAMES-RP and CHARM trials. • Presentations will highlight CIRARA's potential to improve outcomes in LHI patients treated with endovascular therapy and examine 6 and 12-month outcomes from the CHARM trial. • An invited symposium will feature experts discussing advancements in understanding vascular permeability and cerebral edema post-stroke, emphasizing translating research into clinical practice.

TargED Biopharmaceuticals Initiates Phase 1 Trial of TGD001 for Thrombotic Disorders

• TargED Biopharmaceuticals has dosed the first participant in a Phase 1 clinical trial of TGD001, a novel thrombolytic agent. • TGD001 is designed to dissolve clots of various sizes and compositions, addressing conditions like acute ischemic stroke (AIS) and immune-mediated thrombotic thrombocytopenic purpura (iTTP). • The Phase 1 study will assess the safety, tolerability, and pharmacokinetics of TGD001 in healthy volunteers, with initial results expected by mid-2025. • TargED plans to advance TGD001 into Phase 2a trials for AIS and Phase 1b trials for iTTP in the latter half of 2025, following positive safety data.

Tenecteplase Shows Superior Stroke Recovery Outcomes Compared to Alteplase in Meta-Analysis

• A meta-analysis of 11 studies reveals that tenecteplase is associated with a higher likelihood of excellent recovery in ischemic stroke patients compared to alteplase. • Tenecteplase-treated patients showed a 5% greater chance of excellent functional outcome and a 10% reduced risk of disability three months post-stroke. • While both drugs demonstrate similar safety profiles and increase the chances of good recovery, tenecteplase presents a statistically significant advantage. • The findings support the potential shift towards tenecteplase as the preferred thrombolytic agent for acute ischemic stroke within the 4.5-hour window.

Thrombolytic Science Receives FDA Clearance for mproUK Clinical Trial

• Thrombolytic Science (TSI) has received FDA clearance for its Investigational New Drug application for mproUK, a recombinant fibrinolytic pro-enzyme, confirming its safety profile. • The Phase II trial in the UK for myocardial infarction is set to commence following MHRA approval, building on promising Phase II results from the DUMAS trial in stroke patients in the Netherlands. • mproUK offers a potentially safer and more effective reperfusion option for life-threatening thrombotic conditions, with the possibility of earlier blood flow re-establishment. • The treatment approach combines a mini bolus of r-tPA followed by a low dose of mproUK, showing promise in clinical studies with reduced bleeding risk and rethrombosis.

Recombinant Factor 7A Shows Promise in Halting Brain Bleeds After Stroke

• A global study is underway to evaluate Recombinant Factor 7A's efficacy in stopping brain bleeds following a stroke, potentially improving patient outcomes. • The trial focuses on administering the drug within the first few hours of stroke onset, when it is believed to have the greatest impact. • Mobile stroke units are being utilized to expedite treatment, aiming to administer the drug within a critical two-hour window. • The FDA has granted permission for "exception from informed consent" to facilitate rapid treatment in eligible patients.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy